Arctic Bioscience Posts 26% Sales Growth and Prepares EMA Advice for HRO350 Phase 3

Arctic Bioscience reported year-to-date sales revenue of NOK 32.6 million for the first nine months of 2026, up 26% from NOK 25.9 million a year earlier, and said it will begin seeking European Medicines Agency scientific advice on its HRO350 phase 3 design in the fourth quarter. The Norwegian biotech published the update through news.cision.com.

Arctic Bioscience's Nutra Sales and HRO350 Plans

Arctic Bioscience develops pharmaceutical and nutraceutical products from marine compounds and sells ROMEGA-branded nutraceuticals globally. Third-quarter sales revenue was NOK 9.3 million, against NOK 8.7 million in the same quarter of 2025. The Americas generated NOK 14.9 million year to date, more than double the prior-year amount and 46% of total sales revenue, while sales to Asia rose 15% and combined sales to Norway and Europe fell 10%.

Gross margin for the third quarter was 39.7%, compared with 21.6% a year earlier, and the year-to-date margin was 32.6%, up 3.2 percentage points. Adjusted EBITDA was NOK -5.5 million in the quarter, against NOK -7.8 million in the third quarter of 2025, and NOK -17.7 million for the nine months, against NOK -21.4 million. Available liquidity at the end of the period was NOK 1.4 million.

"Higher raw material costs over the past year have required us to increase prices, but we have not seen any material impact on demand," CEO Christer L. Valderhaug said. Medical director Runhild Gammelsæter said analysis of the phase IIb results "are central to designing a phase 3 protocol and will inform discussions with potential partners about further clinical development."

HRO350 Study History in Company Records

According to akta.pro company records, the phase IIb HeROPA study of HRO350 in mild-to-moderate psoriasis enrolled more than 500 patients, with top-line results in October 2024, 12-month sustained data in July 2025 and statistically significant systemic inflammation reduction confirmed in November 2025. The same records show a three-year agreement worth NOK 75 million signed on March 3, 2021 with Smerud Medical Research International to conduct the HeROPA study.

Earlier Arctic Bioscience Updates

Arctic Bioscience said on November 4, 2026 that it would publish the Q3 2026 operational update on November 11 at 07:00 CET, followed by a webcast at 10:00 CET with a Q&A session, according to news.cision.com. On August 20, 2026, the company said it would publish first-half 2026 results on August 27 at 07:00 CET, with a webcast at 10:00 CET.

Arctic Bioscience's Financing Review

The Board is evaluating additional financing initiatives beyond those completed so far in 2026, and further development of the pharmaceutical portfolio is expected to be financed separately. Partnership discussions for HRO350 will continue alongside work on the phase 3 protocol, and further publications from the HeROPA study are expected.